After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...

Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...

Intellia Therapeutics will find it challenging to survive now that its CRISPR gene-editing treatment has been tied to severe, ...

CRISPR Therapeutics AG CRSP shares soared 8.7% in the last trading session to close at $76.78. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 6.54% at $68.29. The stock trailed the S&P 500, which registered a daily gain of 1.56%. On the other hand, the Dow registered a gain ...

A red quarter of a circle with the words 'The Quarter Mark' beside it. A year-long series looking back on the most significant moments of the past 25 years, how they changed our world, and how they ...

Gene editing, led by CRISPR, is expanding rapidly beyond medical applications, offering new opportunities across various biotech industries. Technological breakthroughs are fueling acceleration and ...

NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

Lozano is a rare disease mom, neuroscience Ph.D. candidate at UC Davis, and board member for the PURA Syndrome Foundation. In May, a historic moment in science and medicine was captured in a single ...